SF3B1 and myelodysplastic syndrome: In contrast, SF3B1 mutations, found in up to 80% of MDS cases with ring sideroblasts, are associated with a favorable prognosis, longer leukemia-free survival, and robust erythroid responses to luspatercept, a first-in-class agent targeting the TGF-β superfamily pathway.20,21